Prednisone Recruiting Phase 2 Trials for Metastatic Castration Resistant Prostate Cancer / Castration-Resistant Prostate Cancer (CRPC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03360721Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients
NCT03414034Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer